|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...5758596061626364656667...156157» |
- Enrollment open: A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques (clinicaltrials.gov) - Aug 24, 2015
P1, N=20, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting
- | New P1 trial: A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Aug 24, 2015
P1, N=24, Enrolling by invitation, Sponsor: AbbVie
- Trial primary completion date: The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Aug 22, 2015
P2, N=119, Completed, Sponsor: Chengdu PLA General Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2014 --> Nov 2014
- |||| dalfampridine / Generic mfg.
Trial primary completion date: ENHANCE: Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis (clinicaltrials.gov) - Aug 22, 2015
P3, N=590, Recruiting, Sponsor: Biogen
Trial primary completion date: Aug 2014 --> Nov 2014 Trial primary completion date: May 2016 --> Jan 2016
- Trial primary completion date, HEOR: Effect of Resistance and Aerobic Exercise in CIDP or MMN (clinicaltrials.gov) - Aug 22, 2015
P=N/A, N=36, Enrolling by invitation, Sponsor: University of Aarhus
Trial primary completion date: May 2016 --> Jan 2016 Trial primary completion date: Jun 2015 --> Dec 2015
- || atacicept (VT-001) / Vera Therap
Trial primary completion date: Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II) (clinicaltrials.gov) - Aug 22, 2015
P2b, N=213, Recruiting, Sponsor: EMD Serono
Trial primary completion date: Jun 2015 --> Dec 2015 Trial primary completion date: Apr 2018 --> Nov 2017
- Trial primary completion date, MRI: MRI in Diagnosing and Monitoring CIDP (clinicaltrials.gov) - Aug 22, 2015
P=N/A, N=40, Enrolling by invitation, Sponsor: University of Aarhus
Trial primary completion date: Apr 2018 --> Nov 2017 Trial primary completion date: Jun 2015 --> Sep 2015
- Trial primary completion date, Combination therapy, MRI: The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients (clinicaltrials.gov) - Aug 22, 2015
P4, N=20, Recruiting, Sponsor: Gaylis, Norman B., M.D.
Trial primary completion date: Jun 2015 --> Sep 2015 Trial primary completion date: Sep 2014 --> Sep 2016
- || Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: REFINE: Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) (clinicaltrials.gov) - Aug 22, 2015
P2, N=290, Completed, Sponsor: Biogen
Trial primary completion date: Sep 2014 --> Sep 2016 Trial primary completion date: Jul 2014 --> Apr 2014
- Afrezza (recombinant human insulin inhalation) / MannKind
Trial primary completion date: Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Aug 21, 2015
P1, N=30, Recruiting, Sponsor: Sanofi
Trial primary completion date: Jul 2014 --> Apr 2014 Trial primary completion date: Jan 2016 --> Sep 2015
- || Trial primary completion date: MCP: Ascension (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: Integra LifeSciences Corporation
Trial primary completion date: Jan 2016 --> Sep 2015 Trial primary completion date: May 2015 --> Jan 2020
- dalfampridine / Generic mfg.
Trial primary completion date: Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients (clinicaltrials.gov) - Aug 21, 2015
P4, N=50, Recruiting, Sponsor: Clinique Neuro-Outaouais
Trial primary completion date: May 2015 --> Jan 2020 Trial primary completion date: Jul 2015 --> Dec 2015
- ZB-168 / Zura Bio
Trial primary completion date: A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes (clinicaltrials.gov) - Aug 21, 2015
P1, N=35, Recruiting, Sponsor: Pfizer
Trial primary completion date: Jul 2015 --> Dec 2015 Trial primary completion date: Jul 2015 --> Nov 2015
- autologous hematopoietic stem cell therapy / Northwestern University
Enrollment change, Trial withdrawal, Trial primary completion date: Hematopoietic Stem Cell Support Versus Insulin in T1D (clinicaltrials.gov) - Aug 21, 2015
P1/2, N=0, Withdrawn, Sponsor: Northwestern University
Trial primary completion date: Jul 2015 --> Nov 2015 N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2016 --> Aug 2015
- ||| Tresiba (insulin degludec) / Novo Nordisk
Enrollment open: A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=1000, Enrolling by invitation, Sponsor: Novo Nordisk A/S
N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2016 --> Aug 2015 Not yet recruiting --> Enrolling by invitation
- ||| New trial: Web-based Genetic Research on Lupus (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=5000, Recruiting, Sponsor: 23andMe, Inc.
- ||| New trial: Impact of the Persistence of Inflammation at Doppler Ultrasound Level on the Structural Evolution of Erosion in Rheumatoid Arthritis Treated With Biotherapy (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=100, Recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
- New trial: Continuous Glucose Monitor in Children With Poorly Controlled Diabetes (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=30, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
- ||| mavrilimumab (KPL-301) / Kiniksa
Trial initiation date: A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Aug 21, 2015
P2, N=400, Active, not recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Enrolling by invitation Initiation date: Jan 2013 --> Aug 2012
- | Trial completion: A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects (clinicaltrials.gov) - Aug 20, 2015
P1, N=42, Completed, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 2013 --> Aug 2012 Active, not recruiting --> Completed
- Biomarker, New trial: Biomarkers for the Progression of IgA Nephropathy (clinicaltrials.gov) - Aug 20, 2015
P=N/A, N=120, Completed, Sponsor: Istanbul University
- | Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
New P2 trial: Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Aug 20, 2015
P2, N=40, Not yet recruiting, Sponsor: Astellas Pharma Inc
- Trial completion: Wireless Motion Sensors for Rheumatoid Arthritis Patients - Pilot Study (clinicaltrials.gov) - Aug 20, 2015
P=N/A, N=7, Completed, Sponsor: Cedars-Sinai Medical Center
Active, not recruiting --> Completed Recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Biomarker, Trial completion, Trial primary completion date: Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers (clinicaltrials.gov) - Aug 20, 2015
P=N/A, N=40, Completed, Sponsor: Glostrup University Hospital, Copenhagen
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Sep 2012 --> Jul 2013
- tilarginine (L-NMMA) / Arginox Pharma, Houston Methodist Research Institute
Trial primary completion date: Diameter Changes of Retinal Vessels During Hypoxia (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=60, Recruiting, Sponsor: University of Aarhus
Recruiting --> Completed | Trial primary completion date: Sep 2012 --> Jul 2013 Trial primary completion date: May 2015 --> May 2016
- Enrollment closed, Trial primary completion date: Study of Enzyme Supplements to Treat Celiac Disease (clinicaltrials.gov) - Aug 19, 2015
P1/2, N=40, Active, not recruiting, Sponsor: Heim Pal Children's Hospital
Trial primary completion date: May 2015 --> May 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2009 --> Dec 2014
- Eprex (epoetin alfa) / J&J, Epogen (epoetin alfa) / Amgen
Trial completion: Treatment With Erythropoietin and Cognition During Hypoglycaemia (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=11, Completed, Sponsor: Hillerod Hospital, Denmark
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2009 --> Dec 2014 Active, not recruiting --> Completed
- New trial: Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=12, Completed, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
- New trial: High Intensity Interval Training and Rheumatoid Arthritis (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=26, Not yet recruiting, Sponsor: Duke University
- Biomarker, New trial: Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=150, Enrolling by invitation, Sponsor: University of Aarhus
- | BioChaperone lispro (ultra fast-acting insulin analog) / Adocia
New P1 trial: To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog (clinicaltrials.gov) - Aug 19, 2015
P1, N=36, Not yet recruiting, Sponsor: Adocia
- | namilumab (IZN-101) / Amgen, Izana Biosci, Roivant
Biomarker: Blood Sample Collection Study for Pharmacogenomic Characterization of Participants That Previously Received Namilumab in M1-1188-002-EM (PRIORA, [NCT01317797]) Study (clinicaltrials.gov) - Aug 19, 2015
P1, N=14, Not yet recruiting, Sponsor: Takeda
- Enrollment change, Trial termination: The Role of Traditional Chinese Medicine in the Treatment of Chronic Childhood Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Aug 19, 2015
P2/3, N=7, Terminated, Sponsor: Hadassah Medical Organization
Active, not recruiting --> Completed N=20 --> 7 | Recruiting --> Terminated; Slow recruitment
- ||| Trial completion, Enrollment change: Validation of Standardized Questionnaires on Depression for Rheumatoid Arthritis (RA) (VADERA I) and Investigation of the Frequency of Depression in RA (VADERA II) (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=1004, Completed, Sponsor: Hoffmann-La Roche
N=20 --> 7 | Recruiting --> Terminated; Slow recruitment Recruiting --> Completed | N=1300 --> 1004
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date, Combination therapy: A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage (clinicaltrials.gov) - Aug 18, 2015
P4, N=429, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | N=1300 --> 1004 Trial primary completion date: Jul 2015 --> Jan 2015
- New trial: NIGA-RA: Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy (clinicaltrials.gov) - Aug 18, 2015
P=N/A, N=120, Recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
- New trial: Evaluation by HR-pQCT of Bone Microarchitecture Changes in Patients With Rheumatoid Arthritis Under Anti-TNF Therapy. (clinicaltrials.gov) - Aug 18, 2015
P=N/A, N=14, Terminated, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
- New trial: An ACT Based Application for Young People With Type 1 Diabetes (clinicaltrials.gov) - Aug 18, 2015
P=N/A, N=116, Recruiting, Sponsor: University of Edinburgh
- ||| Benlysta (belimumab) / GSK
Enrollment change: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - Aug 17, 2015
P2, N=60, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Jul 2015 --> Jan 2015 N=40 --> 60
- New trial: Online Cognitive Training in PD, MS and Depressed Patients Treated With Electroconvulsive Therapy (clinicaltrials.gov) - Aug 17, 2015
P=N/A, N=60, Not yet recruiting, Sponsor: VU University Medical Center
- New trial: Tissue Sodium in Autoimmune Disease (clinicaltrials.gov) - Aug 17, 2015
P=N/A, N=21, Not yet recruiting, Sponsor: Vanderbilt University
- New trial: Mussels, Inflammation and Rheumatoid Arthritis (MIRA) (clinicaltrials.gov) - Aug 17, 2015
P=N/A, N=40, Not yet recruiting, Sponsor: Göteborg University
- |||||| Enrollment open: A Clinical Trial Study of Hip System in Primary Total Hip Arthroplasty in China (clinicaltrials.gov) - Aug 17, 2015
P3, N=160, Recruiting, Sponsor: Johnson & Johnson Medical (Suzhou) Ltd.
N=40 --> 60 Not yet recruiting --> Recruiting
- ||||||| Promacta (eltrombopag) / Novartis
Trial completion, Trial primary completion date: EXTEND (Eltrombopag Extended Dosing Study) (clinicaltrials.gov) - Aug 17, 2015
P3, N=302, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Jul 2015
- Trial completion, Enrollment change: Physical Activity in Children With Type 1 Diabetes Study (clinicaltrials.gov) - Aug 17, 2015
P=N/A, N=13, Completed, Sponsor: University of Nottingham
Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Jul 2015 Recruiting --> Completed | N=40 --> 13
- Trial completion, Enrollment change, Trial primary completion date: Melatonin in Relapsing-Remitting Multiple Sclerosis Patients (clinicaltrials.gov) - Aug 15, 2015
P2, N=25, Completed, Sponsor: Tehran University of Medical Sciences
Recruiting --> Completed | N=40 --> 13 Recruiting --> Completed | N=40 --> 25 | Trial primary completion date: Jan 2013 --> Jan 2014
- | New P2 trial: APCam11: Home Testing of Day and Night Closed Loop With Pump Suspend Feature (clinicaltrials.gov) - Aug 14, 2015
P2, N=84, Not yet recruiting, Sponsor: University of Cambridge
- | New P2 trial: PosMTMS: The Impact of Positive Mental Training in Multiple Sclerosis (clinicaltrials.gov) - Aug 14, 2015
P2, N=60, Not yet recruiting, Sponsor: University of Edinburgh
- Enrollment change: PLACATE-MS: Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS (clinicaltrials.gov) - Aug 14, 2015
P2, N=9, Terminated, Sponsor: University of Rochester
Recruiting --> Completed | N=40 --> 25 | Trial primary completion date: Jan 2013 --> Jan 2014 N=20 --> 9
- New trial: Influence of Exercise on the Mobility and Balance of Individuals With Multiple Sclerosis (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=32, Completed, Sponsor: University of Nebraska